AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
173 hedge funds and large institutions have $898M invested in AMAG Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 68 increasing their positions, 49 reducing their positions, and 16 closing their positions.
39% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 49
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
17.53% more ownership
Funds ownership: 112.66% → 130.19% (+18%)
12% more capital invested
Capital invested by funds: $803M → $898M (+$95.6M)
2% more funds holding
Funds holding: 170 → 173 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
26% less call options, than puts
Call options by funds: $5.66M | Put options by funds: $7.63M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JSP
Jackson Square Partners
Larkspur,
California
|
+$59.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.6M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$11.1M |
| 4 |
SEI Investments
Oaks,
Pennsylvania
|
+$10.6M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$9.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$12.1M |
| 2 |
TAM
Tocqueville Asset Management
New York
|
-$4.88M |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$3.62M |
| 4 |
JGC
J. Goldman & Co
New York
|
-$3.05M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$2.93M |
AMAG Hedge Fund Activity: Q2 2018 in Review
173 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q2 2018, worth a combined $898M — up 12% from $803M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new AMAG positions and 16 closed out — a net gain of 4 holders — while 68 added to existing stakes and 49 trimmed.
The largest buyer was Jackson Square Partners, opening a new position worth an estimated $59.2M. The largest seller was Broadfin Capital, exiting entirely with an estimated $12.1M sold.
- 173 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q2 2018, up from 170 in Q1 2018.
- Funds reported $898M of AMAG Pharmaceuticals stock for Q2 2018, up 12% quarter-over-quarter.
- 20 funds opened new AMAG Pharmaceuticals positions in Q2 2018 and 16 closed out, a net change of +4 holders.
- The largest AMAG Pharmaceuticals buyer in Q2 2018 was Jackson Square Partners, an estimated $59.2M added.
- The largest AMAG Pharmaceuticals seller in Q2 2018 was Broadfin Capital, an estimated $12.1M sold.
Based on aggregated 13F filings for Q2 2018.